This week: the most famous peptide on the internet went fully mainstream, and a piece of tough-it-out advice that deserves a grade.

Let's go. ☕

The Wolverine peptide's big week

That pitch has lived in biohacker circles for years. This month, it got a much bigger audience.

Why everyone is suddenly talking about it

U.S. Health Secretary Robert F. Kennedy Jr.'s public support for broader peptide access helped move BPC-157 out of niche forums and into national coverage. Reuters reported this month on both Kennedy's support and a new analysis showing that documented BPC-157 use is rising sharply.

That analysis looked at more than 15 million medical records, identified 1,039 documented BPC-157 users, and found a 33-fold increase in newly documented use between 2020 and 2026. One caveat: the study was released as a preprint and has not yet been peer-reviewed.

At the same time, Johns Hopkins published a review of the gray-market peptide boom and the gap between what is being marketed and what has actually been studied in humans. That is what a mainstream moment looks like. The attention moves fast. The evidence usually does not.

What BPC-157 actually is

BPC-157 is a synthetic 15-amino-acid peptide derived from a fragment of a protein originally isolated from human gastric juice. It has been studied since the early 1990s.

Most of the excitement comes from animal research. Preclinical studies have reported effects in tendon, ligament, muscle, gastrointestinal, and other tissue-healing models. That is where the Wolverine nickname comes from. The animal data are interesting. But animal healing models are not the same thing as proven treatment in people.

The evidence in humans

Human data exist, but they are very limited: a few small early studies involving ulcerative colitis, knee pain, interstitial cystitis, and safety testing. None establishes BPC-157 as an effective treatment for tendon or ligament healing.

No published human trials support the injury-recovery use that drives the hype. A nickname is not an indication, and an endorsement is not a trial.

The compounding question

This part got more confusing after July. The FDA's Pharmacy Compounding Advisory Committee recommended BPC-157-related substances for possible inclusion on the 503A Bulks List. That vote mattered. It did not make BPC-157 FDA-approved, and it did not instantly create a finalized compounding pathway. The FDA still has to make its own decision, and as of this issue, BPC-157 is not on the finalized 503A or 503B Bulks Lists.

FDA staff had recommended against inclusion before the vote, citing limited human evidence along with concerns about immunogenicity, peptide impurities, and characterization of the substance.

So if a clinic offers BPC-157, the useful question is not just “is this coming from a clinic?” It is: where is the product coming from, and under what regulatory pathway is it being provided? A clinical-looking website is not a regulatory category.

The part that connects to last week

Last week we covered the Australian vial sold as retatrutide that contained no retatrutide at all. Testing found undeclared semaglutide instead, at roughly eight times the level found in semaglutide products assessed by the regulator, after a patient was hospitalized with uncontrollable vomiting and a torn esophagus.

That case was not about BPC-157. But it is relevant to the market new BPC-157 users may be entering. When a product sits outside the FDA-approved drug system, the question is not only “does this molecule work?” It is also: is that actually the molecule in the vial?

What to know

• BPC-157 is not FDA-approved. The July advisory vote did not change that.
• Human data exist, but they do not establish the injury-recovery claims driving the current hype.
• If a clinic or telehealth service offers it, asking where the product came from and what regulatory pathway is being used is completely reasonable.
• Suspected adverse reactions or product-quality problems can be reported through FDA MedWatch.

Meanwhile, documented use is rising sharply. Its biggest moment yet. Same unanswered question: does it actually heal human injuries the way the internet says it does? We still do not know.

“You're just supposed to push through the nausea.”

What the evidence says. There is one true thing hiding in that sentence. GI side effects are common with both semaglutide and tirzepatide, especially during dose escalation, and many nausea, vomiting, and diarrhea events do improve with time. So yes, mild symptoms can settle.

But push through it is not a universal treatment plan. GI adverse effects are also an important reason people stop these medications. In Wegovy trials, gastrointestinal adverse reactions led to permanent discontinuation in 4.3% of treated adults versus 0.7% with placebo. With Zepbound, gastrointestinal reactions occurred in 56% of treated participants versus 30% with placebo, and GI symptoms led to treatment discontinuation more often with tirzepatide than placebo.

And not every stomach symptom belongs in the same bucket. Mild nausea that is improving is different from repeated vomiting, difficulty staying hydrated, or severe persistent abdominal pain. Both Wegovy and Zepbound prescribing information include warnings about serious GI reactions, dehydration-related kidney injury, and acute pancreatitis. That is why persistent, worsening, or function-limiting symptoms are a conversation with the prescriber, not an endurance test.

Worth your inbox

Researching health for yourself is one job. Doing it for an aging parent at the same time is two. GrayBrief is a plain-English education resource for adult children navigating elder care: what to ask, what to watch for, and what nobody tells you until it's urgent. If that's your season of life, it's worth a look.

The clinic setting may feel different, but it does not change the biggest facts about the product. BPC-157 is still not FDA-approved, and we still do not have a controlled human trial showing that it heals tendon injuries.

I would ask the clinic two simple questions: where is the product coming from, and under what regulatory pathway is it being provided? That matters because an FDA advisory committee recommended BPC-157 for possible inclusion on the 503A compounding list in July, but the FDA has not made that recommendation final. I would also ask what human evidence supports using it specifically for your tendon injury.

A recommendation from a healthcare professional deserves to be taken seriously. It also deserves the same evidence questions as anything else.

Mais, PharmD, Medical Reviewer, Pep in Her Step

• GLP-1s and PCOS: the full evidence review on weight, cycles, and hormones.
• The GLP-1 vision scare: a lawsuit is making headlines, and we're checking what the evidence says before the fear outruns it.
• Life after GLP-1s: what maintenance actually looks like, from the women already there.